Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. All News
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about CUREVAC N.V.
07:02aCureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
EQ
01/13CUREVAC N : In relation to the Parties' share portfolios in CureVac N.V. (NL-Amsterdam) - ..
PU
01/03CUREVAC N : Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement as..
PU
2021CureVac Stock Slips Following Kempen's Stock Rating Downgrade
MT
2021Kempen Downgrades CureVac to Sell From Neutral, Adjusts Price Target to $20 From $50
MT
2021CUREVAC N.V.(NASDAQGM : CVAC) added to NASDAQ Biotechnology Index
CI
2021CUREVAC N : Interim Condensed Consolidated Statements of Operations and Other Comprehensiv..
PU
2021CureVac N.V. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
2021Berenberg Bank Adjusts CureVac's Price Target to $70 From $123, Maintains Buy Rating
MT
2021UK study finds mRNA COVID-19 vaccines provide biggest booster impact
RE
2021GSK names Pfizer scientist Dormitzer as vaccines R&D head
RE
2021CureVac's Q3 Pretax Loss Widens, Revenue Rises
MT
2021CureVac To Begin Trials Of COVID-19 Vaccine As Animal Testing Shows Strong Antibody Res..
MT
2021CureVac to begin trials for next-generation COVID-19 shots within months
RE
2021CUREVAC N : Announces Financial Results for the Third Quarter and First Nine Months of 202..
PU
2021CUREVAC N : Announces Financial Results for the Third Quarter and First Nine Months of 202..
PU
2021CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021..
EQ
2021CureVac Says Preclinical Trial Shows Antibody Levels of COVID-19 Vaccine Candidate CV2C..
MT
2021CUREVAC N : Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, ..
PU
2021CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, ..
EQ
2021CureVac N.V. Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candida..
CI
2021CureVac Says CV8102 Phase 1 Study's Dose-Escalation Part Shows Immune Response Against ..
MT
2021CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102..
PU
2021CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV810..
EQ
2021CureVac N.V. Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate C..
CI
2021CUREVAC N : Deutsche Bank Starts CureVac at Hold with $35 Price Target
MT
2021CUREVAC N : Shareholder dievini Files Shareholding Change with US Regulator; Stock Down 5%
MT
2021CureVac Shares Down 12%
DJ
2021CUREVAC N : EMA ends rolling review of CVnCoV COVID-19 vaccine following withdrawal by Cur..
AQ
2021CLOSE UPDATE : US Stocks Waver Ahead of Earnings, FOMC Minutes; Investors Remain Cautious ..
MT
2021Health Care Stocks Extending Retreat Ahead of Tuesday Close
MT
2021Equities Choppy Midday as Clarida Says Fed Would Respond to Rise in Inflation Expectati..
MT
2021MIDDAY REPORT : US Stocks Choppy as Clarida Says Fed Would Respond to Rise in Inflation Ex..
MT
2021Health Care Stocks Falling Despite Moderate Rise Among Biotech Companies
MT
2021CUREVAC N : Drops COVID-19 Vaccine to Focus on Second-Generation Shot with GlaxoSmithKline
MT
2021Wall Street Set for Cautiously Higher Open, Earnings Season Eyed
MT
2021Health Care Stocks Edge Higher Premarket Tuesday
MT
2021WALL STREET STOCK EXCHANGE : It's just a period of market normalization
2021CUREVAC N : to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Techn..
PU
2021CUREVAC N : Forgoes COVID-19 Vaccine Candidate; Stock Slips 15%
MT
2021CUREVAC N : to Refocus COVID-19 Vaccine Development Efforts to Second-Generation mRNA Cand..
MT
2021CUREVAC N : to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Techn..
PU
2021CUREVAC N : to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Techn..
EQ
2021CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Techno..
CI
2021Sanofi ditches mRNA COVID-19 vaccine after rivals' success
RE
2021Sanofi ditches mRNA COVID-19 vaccine after rivals' success
RE
2021MODERNA : EU drugs regulator to decide on Pfizer vaccine booster in early October
RE
2021Correction to CureVac 2nd Update Article on Sept. 14
DJ
2021CureVac Cancels mRNA Contracts For COVID-19 Jab
MT
2021CUREVAC N : Contracts with manufacturing partners WACKER and Celonic terminated; Rentschle..
PU
2021APPLE : U.S. stocks close lower on worries over recovery, corporate tax hikes
RE
2021INTUIT : Wall Street dips as choppy recovery, looming tax hikes weigh on sentiment
RE
2021CUREVAC N : Terminates Two Manufacturing Contracts Amid Streamlining of European mRNA Prod..
MT
2021Health Care Stocks Rally Early Tuesday
MT
2021CUREVAC N : Terminates 2 Manufacturing Contracts Amid Streamlining of European mRNA Produc..
MT
2021CUREVAC N : Streamlines European Network for mRNA Product Manufacturing
PU
2021CUREVAC N : Streamlines European Network for mRNA Product Manufacturing
EQ
2021CureVac Streamlines European Network for mRNA Product Manufacturing
CI
2021CureVac Shares Fall Premarket on Termination of Vaccine Contracts With Wacker Chemie, C..
DJ
2021CureVac Terminates Covid Vaccine Manufacturing Contract With Wacker Chemie, Celonic -- ..
DJ
2021Health Care Stocks Add to Early Slide
MT
2021CUREVAC N : CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet (Form 6-K)
PU
2021CUREVAC N : CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
PU
2021CUREVAC N : CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
EQ
2021CureVac N.V.'s CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
CI
2021CUREVAC N : Preclinical Data Shows Sharp Reduction of Liver Fibrosis With mRNA Therapeutic..
MT
2021CUREVAC N : Findings in preclinical mouse models provide first direct proof of efficacy of..
PU
2021CUREVAC N : Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRN..
PU
2021CUREVAC N : Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRN..
EQ
2021CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA..
CI
2021CUREVAC N : Bionity - CureVac's Second-Generation Vaccine Candidate Demonstrates Improved ..
AQ
2021CUREVAC N : GlaxoSmithKline's Next-Generation COVID-19 Vaccine Shows Improved Animal Immun..
MT
2021CUREVAC N : Earnings Flash (CVAC) CUREVAC Posts Q2 Revenue EUR22.4M
MT
2021GLAXOSMITHKLINE : GSK, CureVac's next-gen COVID-19 vaccine shows promise in monkey trial
RE
2021SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Monday
MT
1  2  3  4  5  6Next
Upcoming event on CUREVAC N.V.